Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

Bankers Capital International and BCI LifeSciences Announce Cooperative Agreement for the Life Sciences Industry

NEW YORK, Dec. 14, 2017 /PRNewswire/ -- Bankers Capital International and BCI LifeSciences LLC today announced a cooperative agreement, focused on the life sciences industry. Under the plan, Bankers Capital International and BCI LifeSciences will leverage their respective networks and knowledge base to provide life science companies with executive-level consultancy, strategic planning assistance, and access to institutional capital, worldwide. The companies will operate as correspondents through their mutual corporate headquarters in New York City.

Commenting on the announcement, R. Douglas Hulse, the co-founder and Chief Executive Officer of BCI LifeSciences said: "My team and I have a long history of advising large and small companies in the life sciences industry. We have assisted numerous companies to develop and advance their strategic growth plan, and we have helped to commercialize many technologies and products around the world. Our association with Bankers Capital International will now provide our clients with access to institutional capital and merger or acquisition partners, globally. Gordon and I think that today's announcement marks a quantum expansion of the overall services and consultancy that we can provide our clients."

Todd M. DeMatteo, Senior Executive Director of Bankers Capital International, added: "Our clients engage us based on our knowledge, deal creativity and reach. BCI LifeSciences is a perfect extension of our capabilities and strengths, and we are a perfect continuation of their consulting and advisory services. The combination of our bankers with the expertise of Doug's and Gordon's advisers provides a seamless and compelling talent pool for clients in the life sciences industry."

About Bankers Capital International

Bankers Capital International is a boutique investment bank, headquartered in New York City, focused on multiple sectors in the United States, Asia, Europe, and Latin America. The firm advises middle-market clients on matters such as mergers and acquisitions, management buy-outs, capital raises, restructurings, turnarounds, and strategic planning. Bankers Capital International is registered with the Securities and Exchange Commission (SEC), and the Financial Industry Regulatory Authority (FINRA). The firm is also a member of the Securities Investor Protection Corporation (SIPC).

About BCI LifeSciences LLC

BCI LifeSciences LLC is an advisory firm, comprised of distinguished senior level executives from the life sciences industry. Its team members have advanced operating and transaction experience in biotechnology, pharmaceuticals, medical devices and clinical diagnostics, and its principals have been founders, chairmen, presidents, CEOs and COOs of large multi-national organizations and emerging healthcare companies in the United States and abroad. BCI LifeSciences has extensive experience advising companies and management teams in the life sciences industry from startups to multinationals, worldwide.

About R. Douglas Hulse

Mr. Hulse is the Chief Executive Officer, co-founder and an equity member of BCI LifeSciences LLC. He is also a member of the Company's Board of Managers. Mr. Hulse has over 40 years of origination and operations experience, building and commercializing new businesses. He was a Founder of The Sage Group, a consultancy company focused on biopharmaceuticals, and has held senior level executive positions with a number of multinational and startup companies including: Hemispherx Biopharma, Enzon, Inc., i-STAT Corporation, Sunstone, Inc., Envirometrics and Polycyclose Technologies, SDTX Technologies, Engelhard Industries, Halcon/SD Group. He led negotiations for many of the joint ventures with ARCO Chemical that formed Oxirane Corporation, a $1 billion petrochemical company. Mr. Hulse is a Phi Beta Kappa graduate of Princeton University in Chemistry and holds Masters Degrees in Chemical Engineering Practice and Industrial Management from MIT.

About Gordon V. Ramseier

Mr. Ramseier is the President, co-founder and an equity member of BCI LifeSciences LLC. He has over 40 years of origination and operations experience, building and commercializing new technologies. He was a Founder of The Sage Group and has held senior level executive positions with a number of companies in the life sciences industry, including: OncoTherapeutics, ImmuneTech Pharmaceuticals, Inc. (later Dura Pharmaceuticals), the Healthcare Industries Practice of Booz, Allen & Hamilton, G.D. Searle, and Pfizer Laboratories. Mr. Ramseier received his M.B.A. (with distinction) from the Amos Tuck School of Business Administration, Dartmouth College and his B.S. in Chemistry from Washington & Lee University.

For More Information:

Bankers Capital International
BCI LifeSciences LLC


SOURCE Bankers Capital International

These press releases may also interest you

at 20:34
National Life Insurance Company ("National Life") today announced the expiration of and the results for its previously announced offer to exchange (the "Exchange Offer") any and all of National Life's outstanding 10.50% Surplus Notes due 2039 (the...

at 20:25
Ternio, the blockchain leader bringing transparency to programmatic digital advertising, today named Keith Johnson as Vice President of Product. In his new role based in Atlanta, Johnson will lead Ternio's vision for bringing enterprise-grade...

at 20:05
Restaurant365®, the world's all-in-one, cloud-based, restaurant-specific accounting, back-office and reporting solution, has accomplished record growth in 2018 with 245 new customers to date, bringing the total number of restaurants that use its...

at 20:00
Extraco Banks was honored with the 2018 Financial Capability Innovation Award presented by the nation's leading technology innovator, EVERFI, Inc. The award recognizes Extraco's significant efforts to improve the financial capability of central...

at 20:00
MMA Capital Management, LLC  (the "Company") today announced that the Company expects to file its Quarterly Report on Form 10-Q for the period ended June 30, 2018, (the "Second Quarter 2018 Report") with the Securities and Exchange Commission on...

at 19:30
On July 1, 2018, Attorney Christopher I. Jacobs of Kalfus & Nachman, P.C. was named a member of the Supreme Court of Virginia's Medical Malpractice Review Panel (MMRP). This voluntary service is vital to the work of the state's highest court. The...

News published on 14 december 2017 at 14:34 and distributed by: